S Wang, P Wei, Y Zhang, S Zhang - Polymer Testing, 2023 - Elsevier
Melphalan is an efficient chemotherapeutic agent for retinoblastoma (RB) in clinical practice. However, the problems of drug resistance and poor prognosis caused by long-term …
X Gu, M Xie, R Jia, S Ge - Frontiers in medicine, 2021 - frontiersin.org
Background: Retinoblastoma is the most common primary intraocular malignancy of childhood. Despite high survival and eye salvage as the result of various types of therapies …
The most prevalent paediatric vision-threatening medical condition, retinoblastoma (RB), has been a global concern for a long time. Several conventional therapies, such as systemic …
K Jiang, X Fan, Y Hu, S Yao, Y Liu, C Zhan, W Lu… - Biomaterials, 2022 - Elsevier
Retinoblastoma is the most common primary intraocular malignancy in infancy with a metastases-related death risk. However, a safe and convenient treatment without …
Background: Active vitreous seeds in eyes with retinoblastoma (Rb) adversely affects the treatment outcome. This study aimed to investigate the safety and efficacy of intravitreal …
YA Yousef, M Mohammad, I Al-Nawaiseh… - Ophthalmic …, 2023 - Taylor & Francis
Purpose We present an epidemiologic analysis of retinoblastoma (RB) and uveal melanoma (UM) in Jordan to aid national strategies for improved ocular cancer surveillance and …
G Alahmadi, AMY Maktabi, G Sesma… - Clinical …, 2023 - Taylor & Francis
Purpose To evaluate the efficacy of intravitreal chemotherapy for vitreous seeding in patients with retinoblastoma (Rb). Design Retrospective, single-arm cohort study. Methods This study …
Aim To investigate whether the American Joint Committee on Cancer (AJCC) clinical category cT2b needs to be subclassified by the type and distribution of retinoblastoma (RB) …
T Bilbeisi, R Almasry, M Obeidat, M Mohammad… - Frontiers in …, 2023 - frontiersin.org
Purpose To analyze causes and prognostic factors for death among Retinoblastoma (Rb) patients treated at a single specialized tertiary cancer center in Jordan. Methods We …